How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.

Name

Receptor-Tyrosine Kinase Inhibitors - Inhibitors of Uncontrolled Cell Replication and Other Diseases Caused by Receptor-Tyrosine Kinase

Organization name

Enterprise Europe Network

Profile

Description

The German Research Institute prepares inhibitors which represent a derivative of indolin-2-on substituted at the C3 atom, and which inhibit the activity of receptor-tyrosine kinase. Receptor tyrosine kinase are often involved in uncontrolled cell replication, disturbed apoptosis, filariasis, or a disease dependent on angiogenesis.
The inhibitors are low-molecular inhibitors entering cells which, single or in combination, block the activity of receptor-tyrosine kinase.
The receptor-tyrosine kinases are primarily VEGFR-3 (Vascular Endothelial Cell Growth Factor Receptor), VEGFR-2, Tie2, EGFR (Epidermal Growth Factor Receptor), ErbB2, IGF1R, and FGFR1 (Fibroblast Growth Factor Receptor) which, for instance, are involved in angiogenesis. The inhibitors can be used both when looking for pharmaceutical lead structures and as tools in molecular biology, for instance as selective ATP-competitive inhibitors of phosphorylation of VEGFR-3 kinase.

Innovations and advantages of the offer

The inhibitors can be used both when looking for pharmaceutical lead structures and as tools in molecular biology.

Current and Potential Domain of Application

Biotechnology, pharmaceutical industry.

Current Stage of Development

Development phase - Laboratory tested

Collaboration Type

  • License Agreement
  • Joint further development

Comments

  • Type of partner sought: industry, research organisation.
  • Specific area of activity of the partner: manufacturer in the field of biotechnology or pharmaceutical industry regarding inhibitors.
  • Task to be performed by the partner sought: license the technology or joint further development. 

Ref: 12 DE 1380 3O09

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.

 
 

latest entries